An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called tipifarnib in patients with advanced solid tumors that contain mutations in a gene called HRAS. Laboratory studies have suggested that tipifarnib may be more effective against cancers with HRAS mutations. Examples of these cancers include some thyroid, bladder, skin, and salivary cancers.
Tipifarnib works by inhibiting an enzyme involved in cancer growth called farnesyltransferase. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor that has continued to grow despite prior therapy and contains an HRAS mutation.
- At least 2 weeks must pass between completing prior chemotherapy or radiation therapy and entering into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alan L. Ho at 646-888-4235.